

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/012728 A1

(51) International Patent Classification?: A61K 31/35,
45/00

CH-4104 Oberwil (CH). GASSER, Jürg, Andreas
[CH/CH]; Im Drissel 59, CH-4104 Oberwil (CH).
GREEN, Jonathan [GB/CH]; Waldstrasse 12, CH-4144
Arlesheim (CH).

(21) International Application Number:
PCT/EP2003/008377

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual
Property, CH-4002 Basel (CH).

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM,
TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:
0217636.0 30 July 2002 (30.07.2002) GB
60/425,482 12 November 2002 (12.11.2002) US

(84) Designated States (regional): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

Published:
— with international search report

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): BHATNAGAR,
Ajay, S. [CH/CH]; Geispelgasse 13, CH-4132 Muttenz
(CH). EVANS, Dean, Brent [GB/CH]; Langegasse 11,

WO 2004/012728 A1

(54) Title: COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE

(57) Abstract: The present invention provides a combination for the treatment of a disease or condition which responds to aromatase inhibition, in particular a proliferative disease, especially a malignant disease such as breast cancer or similar soft tissue-endocrine-sensitive cancer, most preferably breast cancer, comprising an aromatase inhibitor and a bisphosphonate for simultaneous, concurrent, separate or sequential use in the prevention of bone loss which is caused by the treatment with an aromatase inhibitor. Also provided is a method of treating a patient suffering from a disease or condition which responds to aromatase inhibition comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an aromatase inhibitor.